← Back to Clinical Trials
Recruiting NCT05296720

NCT05296720 EEG and Behavioral Correlates of Temporal Prediction in the Tactile Modality in Schizophrenia

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05296720
Status Recruiting
Phase
Sponsor Centre Psychothérapique de Nancy
Condition Schizophrenia
Study Type INTERVENTIONAL
Enrollment 68 participants
Start Date 2023-04-13
Primary Completion 2027-04

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 60 Years
Study Type INTERVENTIONAL
Interventions
Tactile stimulation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 68 participants in total. It began in 2023-04-13 with a primary completion date of 2027-04.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Patients with schizophrenia have disturbances in their sense of self, particularly their bodily self. Disorders of the sense of self are central to schizophrenia and are of interest because they are thought to be present prior to the development of the disorder, when only a few attenuated symptoms signal a risk of developing psychosis. Finding markers related to the sense of self would make it possible to predict which subjects, among those with minimal psychotic symptoms, will develop psychosis, and thus to better adapt management. Disturbances in the experience of the passage of time that accompany disturbances in the sense of self have been described particularly in subjects at risk of developing psychosis, and would predict the onset of the pathology. However, as with alterations in the sense of self, it can be difficult to get patients to describe their disturbances in the experience of time, and objective measures are required to facilitate detection of these disturbances. In the present protocol an objective measure of temporal perception mechanisms will be tested in relation to the sense of self. The tests used in the protocol assess subjects' abilities to benefit from the passage of time and to use these abilities to predict and prepare for the occurrence of an event. The investigators have previously shown that patients with impaired bodily sense of self do not benefit from the passage of time to prepare themselves to process information in the future. The present protocol is aimed at developing a measure more sensitive to the patients' disorders by adding tactile measures.

Eligibility Criteria

Inclusion Criteria: * Male or Female; * Age between 18 and 60 years inclusive; * Subject who has dated and signed the consent form (guardian or custodian prior to the commencement of any trial-related procedures if applicable); * Enrolled in a social security plan or beneficiary of such a plan. Exclusion Criteria: * Psychoactive substance use disorders (as defined by DSM-V); * Use of benzodiazepines (in the period prior to inclusion, for a duration equivalent to 5 half-lives of the product), cannabis (in the 2 months prior to inclusion; use of cannabis (THC) will be verified with a urine dipstick) or hallucinogenic substances (in the period prior to inclusion, for a duration equivalent to 5 half-lives of the product); * Neurological pathology or sequelae; * Attention deficit hyperactivity disorder (ADHD); * A borderline personality disorder; * Disabling sensory disorders; * Person deprived of liberty or under court protection; * Pregnant, parturient or nursing woman; * Subject in a period of exclusion as defined by another clinical study.

Contact & Investigator

Central Contact

Anne GIERSCH, MD PhD

✉ anne.giersch@inserm.fr

📞 0388116471

Principal Investigator

Anne GIERSCH, MD, PhD

PRINCIPAL INVESTIGATOR

Institut National de la Santé Et de la Recherche Médicale, France

Frequently Asked Questions

Who can join the NCT05296720 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 60 Years, studying Schizophrenia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05296720 currently recruiting?

Yes, NCT05296720 is actively recruiting participants. Contact the research team at anne.giersch@inserm.fr for enrollment information.

Where is the NCT05296720 trial being conducted?

This trial is being conducted at Strasbourg, France.

Who is sponsoring the NCT05296720 clinical trial?

NCT05296720 is sponsored by Centre Psychothérapique de Nancy. The principal investigator is Anne GIERSCH, MD, PhD at Institut National de la Santé Et de la Recherche Médicale, France. The trial plans to enroll 68 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology